NewsDialy

60 Degrees Pharmaceuticals Locks In Rights to Castanospermine for Tick-Borne Disease Research

7/8/2026

An exclusive option agreement gives one company the right to negotiate a full license for a technology before any competing party can step in.

That is the structure 60 Degrees Pharmaceuticals (Nasdaq: SXTP) has reached with Florida State University, centered on a compound called castanospermine and its potential against tick-borne diseases.

The arrangement extends the company's infectious disease pipeline into a therapeutic area it had not previously claimed. What the option agreement actually covers An option is a reserved position, not a purchase.

The party holding it has paid for the right to pursue a full development license, but the research and intellectual property stay with the originating institution until a complete agreement is struck.

Keep reading

Read the full story

Open on NewsDialy